Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M42,384Revenue $M2,820Net Margin (%)12.7Z-Score23.4
Enterprise Value $M41,906EPS $3.1Operating Margin %30.6F-Score4
P/E(ttm))134Cash Flow Per Share $-2.0Pre-tax Margin (%)28.6Higher ROA y-yN
Price/Book16.510-y EBITDA Growth Rate %0Quick Ratio5.1Cash flow > EarningsY
Price/Sales17.45-y EBITDA Growth Rate %0Current Ratio5.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %22.0ROA % (ttm)10.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)15.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M102ROI % (ttm)53.3Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNVanguard Health Care Fund 2014-12-31 Add0.12%$328.07 - $434.95
($393.59)
$ 412.515%Add 4.49%2,921,000
REGNRay Dalio 2014-12-31 Add0.03%$328.07 - $434.95
($393.59)
$ 412.515%Add 637.5%11,800
REGNAndreas Halvorsen 2014-12-31 Sold Out -1.6%$328.07 - $434.95
($394.04)
$ 412.515%Sold Out0
REGNJoel Greenblatt 2014-12-31 Sold Out -0.01%$328.07 - $434.95
($394.04)
$ 412.515%Sold Out0
REGNKen Fisher 2014-09-30 Buy $296.41 - $364.41
($335.27)
$ 412.5123%New holding, 583 sh.583
REGNJoel Greenblatt 2014-09-30 Add$296.41 - $364.41
($335.27)
$ 412.5123%Add 60.05%1,410
REGNAndreas Halvorsen 2014-09-30 Reduce-2.35%$296.41 - $364.41
($335.27)
$ 412.5123%Reduce -63.53%1,080,682
REGNRay Dalio 2014-09-30 Reduce-0.04%$296.41 - $364.41
($335.27)
$ 412.5123%Reduce -91.3%1,600
REGNAndreas Halvorsen 2014-06-30 Add2.39%$277.29 - $313.74
($296.6)
$ 412.5139%Add 181.75%2,963,456
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 412.5139%Add 60.34%2,795,500
REGNFrank Sands 2014-06-30 Add0.64%$277.29 - $313.74
($296.6)
$ 412.5139%Add 22.32%4,907,362
REGNRay Dalio 2014-06-30 Buy 0.04%$277.29 - $313.74
($296.6)
$ 412.5139%New holding, 18400 sh.18,400
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 412.5139%New holding, 2295 sh.2,295
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 412.5139%New holding, 881 sh.881
REGNAndreas Halvorsen 2014-03-31 Buy 1.3%$267.62 - $347.62
($307.2)
$ 412.5134%New holding, 1051800 sh.1,051,800
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 412.5135%Add 23.47%1,743,468
REGNFrank Sands 2014-03-31 Add0.22%$267.62 - $347.62
($307.2)
$ 412.5134%Add 7.48%4,012,062
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 412.5134%New holding, 6084 sh.6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 412.5144%Sold Out0
REGNFrank Sands 2013-09-30 Add0.56%$227.65 - $309.174
($262.76)
$ 412.5157%Add 20.34%3,777,357
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
REGN Ray Dalio 2014-12-3111,8000.010.04+637.5%
REGN Ron Baron 2014-12-317,4900.010.01+5.36%
REGN Vanguard Health Care Fund 2014-12-312,921,0002.872.8+4.49%
REGN Frank Sands 2014-12-314,986,1774.94.9+0.38%
REGN Mario Gabelli 2014-12-312,19000
REGN Ken Fisher 2014-12-3152400-10.12%
REGN Joel Greenblatt 2014-12-31000Sold Out
REGN Andreas Halvorsen 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
McCorkle Douglas SVP Controller and Asst Treasur 2015-02-27Sell3,000$416.24-0.9view
Tessier-Lavigne MarcDirector 2015-02-26Sell3,000$421.95-2.24view
Terifay Robert JSVP Commercial 2015-02-24Sell11,173$423.67-2.63view
Aberman Michael SSVP Strategy Investor Relation 2015-02-24Sell3,374$418.48-1.43view
Van Plew Daniel PSVP & General Mgr Industrial O 2015-02-23Sell9,431$427.82-3.58view
GOLDSTEIN JOSEPH LDirector 2015-02-20Sell5,000$423.65-2.63view
BROWN MICHAEL SDirector 2015-02-20Sell1,000$422.72-2.42view
RYAN ARTHUR FDirector 2015-02-20Sell29,250$423.01-2.48view
SING GEORGE LDirector 2015-02-20Sell15,000$423.12-2.51view
Aberman Michael SSVP Strategy Investor Relation 2015-02-17Sell3,692$404.461.99view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    1 Feb 23 2015 
    1 Feb 23 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 
    Weekly Top Insider Sells: REGN May 27 2013 


    More From Other Websites
    Novartis treatment for vision loss meets goals in study Feb 27 2015
    The Zacks Analyst Blog Highlights: Pharmacyclics, Celgene, Amgen and Regeneron - Press Releases Feb 27 2015
    Up and Down the Ladder: The Latest Comings & Goings at Alkermes, Charles River Labs and… Feb 27 2015
    REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Feb 27 2015
    EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to... Feb 26 2015
    EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to... Feb 26 2015
    Lightning Round: This group goes higher tomorrow Feb 25 2015
    Cramer Remix: Where's the Nasdaq bubble? Feb 23 2015
    Cramer: Watch out - regulators are gunning for these stoc... Feb 23 2015
    Lightning Round: Don't listen to this CEO Feb 23 2015
    Regeneron Shares Reach Full Valuation Feb 23 2015
    Lightning Round: This stock's got to get game back Feb 20 2015
    FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Feb 20 2015
    Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog Feb 19 2015
    Update: Regeneron: Too Much Excitement About Eylea News? Feb 19 2015
    Regeneron Pharms downgraded by ROTH Capital Feb 19 2015
    REGENERON PHARMACEUTICALS INC Financials Feb 19 2015
    Regeneron Tops Roche in Eye Drug Study That May Boost Sales Feb 19 2015
    Regeneron: Need fair drug prices Feb 19 2015
    NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept)... Feb 18 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK